Skip to main content
Annals of Neurosciences logoLink to Annals of Neurosciences
. 2026 Jul 2:09727531261453688. Online ahead of print. doi: 10.1177/09727531261453688

Integrative Transcriptomic Analysis Identifies Hypoxia-responsive Cell Cycle Hub Genes as Prognostic Markers in Glioblastoma

Manish K Sharma 1, Jonita Chongtham 2, Ashish Bhushan 2, Kunzang Chosdol 1, Subrata Sinha 1,✉, Tapasya Srivastava 2,✉
PMCID: PMC13328107  PMID: 42405025

Abstract

Background

Glioblastoma (GBM) is the most aggressive primary brain malignancy, characterised by hypoxia-driven proliferation, therapeutic resistance and poor prognosis. While hypoxia-induced transcriptional changes are well documented, the temporal regulation of cell cycle genes under sustained hypoxia remains unclear.

Purpose

This study aimed to profile transcriptomic alterations induced by graded hypoxia and identify key hypoxia-responsive regulatory genes in GBM.

Methods

U87MG cells were cultured under normoxia and graded hypoxia (1–3 days), and experimental data of U87MG and LN229 GBM cells were utilised for validation and addressing heterogeneity. Differentially expressed genes (DEGs) were identified and analysed using STRING, Cytoscape, MCODE and CytoHubba to construct protein–protein interaction networks and extract hub genes. Functional enrichment was assessed through DAVID, ClueGO and KEGG, while prognostic relevance was evaluated using GlioVis and ONCOMINE data sets. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) validated hub gene expression dynamics.

Results

A total of 275 DEGs formed two main functional modules enriched in cell cycle regulation and chemokine signalling. Eighteen hub genes (KIF20A, KIFC1, CCNB1, AURKA, EGR1, CDCA3, CENPF, CDCA2, ASPM, KIF11, CCL2, CXCL8, CCNA2, DLGAP5, RACGAP1, TPX2, PTGS2 and CTGF) were significantly associated with mitotic processes and GBM progression. Survival analysis demonstrated that 17 hub genes correlated with poor overall survival (p < .05). qRT-PCR confirmed that hub gene expression peaked during early hypoxia and declined with prolonged exposure, indicating dynamic regulatory adaptation.

Conclusion

These findings identify key hypoxia-responsive genes governing cell cycle progression and immunomodulation in GBM, highlighting their prognostic value and therapeutic potential in GBM.

Keywords: Glioblastoma, hypoxia, cell cycle regulation, hub genes, prognosis, bioinformatics

Introduction

Gliomas are the most common neoplasms of the central nervous system, significantly impairing brain function. Among these, high-grade gliomas (WHO grades 3 and 4), particularly glioblastoma (GBM, WHO grade 4), rank among the most aggressive human cancers, with a median survival of only 12–15 months despite multimodal treatments including surgery, radiotherapy and chemotherapy. 1 GBM is notable for its extensive hypoxic regions, which are closely linked to anti-apoptotic mechanisms, tumour recurrence, therapeutic resistance and enhanced invasiveness, culminating in a highly malignant phenotype and poor clinical outcomes. 2 These challenges underscore the urgent need to decipher the molecular drivers that connect hypoxia with glioma progression.

Tumour hypoxia arises when oxygen demand surpasses supply due to rapid cellular proliferation and abnormal vasculature. Under hypoxic stress, glioma cells engage in complex transcriptional and non-transcriptional adaptations that facilitate survival, angiogenesis, invasion and resistance to therapy. 3 These adaptations are primarily orchestrated by hypoxia-inducible factors, which intersect with critical regulators of the cell cycle such as c-Myc, p53, cyclin D1 and Aurora kinase A (AURKA). 4

Histopathological features frequently observed in GBM, including nuclear atypia, multinucleation and failed cytokinesis, reflect profound dysregulation of cell cycle control, promoting genomic instability and driving malignancy. 5 Although hypoxia is recognised as a key factor enhancing glioma aggressiveness, its specific impact on cell cycle regulation, particularly the contrasting effects of acute versus chronic hypoxia, remains incompletely understood. Emerging evidence indicates that acute hypoxia may stimulate proliferation, whereas chronic hypoxia can suppress DNA replication, alter checkpoint control and induce dormant-like cellular states.6, 7 This duality emphasises the necessity for systematic evaluation of hypoxia-mediated changes in cell cycle-associated gene networks.

Recent advances in high-throughput transcriptomic profiling combined with protein–protein interaction (PPI) network analysis have enabled the identification of hub genes and key molecular pathways involved in cancer progression. In gliomas, molecules such as cyclins, kinesins and cell division cycle associated (CDCA) proteins have emerged as pivotal drivers of proliferation and invasion; however, their expression dynamics in the context of hypoxia remain poorly characterised. 8

Based on the recent literature, a robust research gap in the field of hypoxia’s role in glioma biology is evident. Although numerous studies describe hypoxia-induced gene expression changes, there remains a lack of comprehensive understanding regarding the temporal dynamics of hypoxia-driven transcriptional regulation, particularly in relation to cell cycle hub genes in GBM. While static gene expression snapshots are common, the complex adaptive transcriptional responses over time, especially under sustained hypoxia, are underexplored. Additionally, there is insufficient integration of transcriptomic data with functional network analyses to identify critical regulatory hubs that could serve as precise therapeutic targets. Addressing these gaps through dynamic, systems-level investigations could significantly enhance our understanding of glioma progression and resistance mechanisms under hypoxic stress. Our findings provide new and comprehensive insights into the complex transcriptional remodelling of glioma cells in response to hypoxic stress, revealing dynamic regulatory networks that govern adaptation, proliferation and survival in the hypoxic tumour microenvironment. By identifying key hypoxia-responsive hub genes with prognostic significance, this study not only enhances understanding of GBM biology but also highlights promising molecular biomarkers that could inform patient prognosis and guide the development of targeted therapeutic strategies aimed at overcoming hypoxia-driven treatment resistance.

Material and Methods

Cell Culture

U87MG cells procured from ATCC were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Sigma-Aldrich, Germany) supplemented with 10% FBS (heat-inactivated) and 10 µg/mL of Ciprofloxacin (Sigma-Aldrich, US) at 37°C and 5% CO2. Cultures were regularly checked for mycoplasma contamination. Trypsin-EDTA (Gibco) was used to de-adhere the cells for subculture. Hypoxic conditions were established using a regulated Anoxomat system (Mart Microbiology) in which the cells were incubated in chambers flushed with pre-set oxygen concentrations. Hypoxia at 0.1% O2 was given for 24, 48 and 72 h with media replenished every second day during the culture. The available whole transcriptome data set (GSE27523) of LN229 GBM cells treated with siHIF-1α, siHIF-2α and scrRNA, cultured in hypoxia (1% O2), was analysed.

Ribonucleic Acid Isolation and Microarray

Ribonucleic acid (RNA) was isolated from cultured cells using TriReagent (Sigma-Aldrich, Germany). RNA was then treated with DNase (MBI Fermentas, USA). To inactivate the DNase, 0.1 volume of DNase inactivation reagent was added and quantified by a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, USA). The optical densities (OD) were measured at 260 and 280 nm spectrophotometrically, and the quality of RNA was further checked on a Bioanalyzer before proceeding with the microarray. The RNA Integration Numbers of more than 9.0 were further processed for microarray. Microarray was performed on an Illumina Beadchip HT-12 v3 in a commercial facility for the U87MG data set. Microarray images were analysed by using Genome Studio 2011.3 software (Illumina), where the data were pre-processed and normalised at the probe level. Background correction was performed, and multiple testing corrections were applied. Probes with low expression (e.g., those below background or not expressed in the majority of samples) were filtered out prior to downstream analysis. Subsequently, probe intensities were collapsed to gene symbols by mean, and differential gene expression analysis was performed at the gene level. Log2 ratios of differentially expressed genes (DEGs) were calculated and utilised to analyse pathways significantly altered in hypoxia. Differential expression was assessed using fold change-based criteria.

Differential score = Treatment signal/Control signal

Log2 ratio = Log2 differential ratio; fold change = 2(Log2 ratio)

Microarray data set (GSE27523) of LN229 GBM cells comprising the experimental conditions hypoxia siHIF-1α, hypoxia siHIF-2α and untreated scrambled hypoxia were analysed in triplicate for microarray profiling. Pairwise comparisons between the averages of each set were made with a scrambled hypoxia control. Fold change and p value (<.5) were calculated to determine whether the HIF-mediated response in the 17 genes identified from the survival analysis reverted in the absence of hypoxia-inducible factors.

Protein Isolation and Western Blotting

Cultured GBM cells were lysed in triple detergent lysis buffer containing protease inhibitors. To ensure equal loading, the protein in the cell lysate was quantified using a BCA protein estimation kit. Lysates were resolved on 10% SDS-PAGE and electroblotted onto a nitrocellulose membrane. Anti-VEGFA, anti-CA9 and anti-β-actin (Abcam, USA) antibodies were used as primary antibodies for hybridisation to detect the specific proteins. For secondary binding, the blot was incubated with alkaline phosphatase/HRPO-conjugated goat anti-mouse/anti-rabbit antibody (Santa Cruz Biotechnology Inc., California) and developed in a Chemidoc system.

Bioinformatic Analysis

Differential Expressions Gene Analysis

DEGs were identified based on classification into three hypoxic conditions: 24 h, 48 h and 72 h with respect to normoxia in glioma cells (logFC > 1 or logFC < −1, p value < .05). The overlapping DEGs among these three hypoxic conditions were also identified by a Venn diagram (http://bioinformatics.psb.ugent.be/webtools/Venn/).

Functional Enrichment Analysis of Common Differentially Expressed Genes (1–3 Days)

Functional enrichment analysis plays a vital role in annotating the large-scale biological attributes based on rigorous statistical methods in high-throughput genomic studies. Pathway enrichment analysis and key Hallmark gene sets of DEGs were performed with the Metascape online tool. 9 Metascape is a web-based tool for functional annotation of genes that identifies large-scale databases, including Hallmark Gene Sets and Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways.

Establishing Protein–Protein Interaction Network and Analysis of Module and Hub Gene

The Search Tool for the Retrieval of Interacting Genes (STRING, version 11.5) is a web tool application for evaluating the PPI networks based on computational prediction methods, public text collections and web resources of experimental data. 10 To build the PPI network, overlapping DEGs were submitted to STRING, version 11.5, and then visualised using Cytoscape software (version 8.0; http://cytoscape.org/). 11 The selection criteria were maximum number of interactors = none/query proteins only and confidence score ≥0.4. Furthermore, module analysis was performed to generate the crucial cluster modules using Molecular Complex Detection (MCODE) in Cytoscape. MCODE identifies densely connected regions based on node weighting (local neighbourhood density), seed selection and outwards cluster expansion. Clusters were ranked by the MCODE score (density × number of nodes), which reflects both intra-cluster connectivity and size. Following standard practice, clusters with a score > 5 and sufficient node size were considered biologically meaningful. In our network, six clusters were identified; however, two major modules (Clusters 1 and 3) were prioritised based on a combination of higher MCODE scores, node counts and edge density, as well as biological interpretability. The significant modules were further enriched in DAVID to identify the key biological processes and KEGG pathways associated with these modules. The CytoHubba application in Cytoscape software has been further applied to identify hub proteins, which are core nodes with numerous interacting partners. 12 The top 30 genes were identified based on five topological parameters: closeness, degree, edge percolated component (EPC), maximal clique centrality (MCC) and maximum neighbourhood component (MNC). To explore the hub genes, a Venn diagram was generated using intersections of the top thirty genes obtained from the above five algorithms with the help of an online tool. These significant hub genes were further established by the intersection between the MCODE module genes and Cytohubba hub genes from the CytoHubba plugin.

Validation of Significant Hub Gene Using Oncomine and Gliovis

The mRNA expression level of the significant hub genes was further measured in GBM versus normal brain tissue and validated using Gliovis 13 and Oncomine. 14 Both databases are user-friendly web tools for data visualisation and exploration of brain tumour expression data sets. In the Gliovis web tool, RNA-seq expression data of TCGA GBM-HGG- HG-U133A array consisted of 528 GBM tumours and 10 normal brain samples. Furthermore, expression levels of hub genes were also measured between 515 GBM and 152 low-grade gliomas using the TCGA GBM-LGG data sets. Expression of these genes was represented as boxplots wherein values are given as the mean ± SD. Tukey’s Honest Significant Difference test was performed, and p values of the pairwise comparisons are indicated as ***p < .001; **p < .01; *p < .05; and ns, not significant. The ONCOMINE microarray database was further used to check the mRNA expression levels of hub genes. Oncomine helps to investigate the gene rank (median rank for one target gene) as an overall analysis. The threshold was set at p = .05, a two-fold change and the top 10% gene rank. It compares the GBM versus normal brain tissue analysis, which includes 272 GBM and 50 normal brain tissue from seven data sets (Bredal Brain 2, Lee Brain, Liang Brain, Murat Brain, Shai Brain, Sun Brain and TCGA Brain).

Survival Analysis of Hub Genes

Survival data were obtained from Gliovis for glioma patients. A Cox proportional hazards model p < .05 was considered significant, and associated data analysis was displayed in a Kaplan Meier plot.

Complementary Deoxyribonucleic Acid Synthesis and Quantitative Reverse Transcription Polymerase Chain Reaction for Validation of Selected Genes

First-strand cDNA was synthesised using the MMLV Reverse Transcriptase Kit (MBI Fermentas, USA) and random decamers. Real-time RT-PCR was performed using SYTO-9 (Invitrogen, Carlsbad, USA) on a RotorGene 6000 real-time PCR machine (Corbett Research, Australia). The relative fold change of gene expression was calculated by the ∇∇CT method. 18s was used as the internal control or reference gene, and the qRT-PCR data have been represented as fold change ± standard error mean.

Results

Hypoxia Induces Morphological Alterations and Transcriptomic Reprogramming in Glioblastoma Cells

U87MG GBM cells were cultured under normoxia (20% O2) or hypoxia (0.1% O2) for 24 h (1DH), 48 h (2DH) and 72 h (3DH). Hypoxia induction was verified by nuclear stabilisation of HIF-1α as shown by western blotting (Figure 1A). Consistent with HIF activation, VEGF-A and CA9 protein levels were increased in hypoxic cells compared with normoxic controls at all time points (Figure 1B). Transcript levels of canonical hypoxia markers, including GLUT1, CA9 and VEGFA, were also significantly upregulated in 1DH, 2DH and 3DH (Figure 1C). Together, these findings confirmed robust activation of the hypoxia signalling pathway.

Figure 1. Hypoxia Induces Morphological and Transcriptomic Alterations in Glioblastoma (GBM) Cells.

Figure 1.

Notes: (A) The induction of HIF-1α protein at various time points in hypoxic conditions was detected by western blotting. (B) Increased protein expression of hypoxia signature genes CA9 and VEGF in 0.1% hypoxia compared to normoxia. (C) Increased transcript expression of known hypoxia-responsive genes: GLUT1, VEGFA and CA9 in 0.1% hypoxia compared to normoxia confirmed induction of hypoxia signalling in the cultured cells. N: normoxia; 20% O2, 1DH: 1 day hypoxia, 2DH: 2 day hypoxia, 3DH: 3 day hypoxia. (D) Photomicrographs (100×, 200× and 400×) of U87MG cells, which have been cultured in normoxia (20% O2) (Panel a–c) and hypoxia (0.1% O2). The remaining panels represent the hypoxia treated at 1st day (1DH, d–f), 2nd day (2DH, g–i) and 3rd day (3DH, j–l). Arrows point to dividing cells, cytoplasmic condensation and vacuolisation. (E) Venn diagram of 146 overlapping upregulated genes in 1DH, 2DH and 3DH. (F) Venn diagram of 116 overlapping upregulated genes in 1DH, 2DH and 3DH. (G) List of genes upregulated and downregulated in all three hypoxic conditions, as well as genes that were upregulated in 1DH but downregulated in 2DH and 3DH. (H) Top enrichment scores of KEGG pathway enrichment analysis. The p value indicates the significance of the pathway term correlated to hypoxia. A smaller p value corresponds to a more significantly enriched pathway. p value cutoff is .05. KEGG, Kyoto Encyclopaedia of Genes and Genomes. (I) Gene Ontology (GO) enrichment analysis of genes based on biological processes. The x-axis displays several differentially expressed genes; y-axis indicates GO terms. p value cutoff is .05.

The induction of hypoxia was accompanied by morphological changes in U87MG cells. Cells displayed nuclear condensation and cytoplasmic vacuolisation, with abnormalities in cell division becoming more pronounced after prolonged hypoxia (72 h) (Figure 1D). These structural alterations suggest a direct effect of oxygen deprivation on cell cycle regulation.

To further characterise the molecular consequences of hypoxia, we performed transcriptomic profiling by microarray. DEG analysis (fold change ≥1.5 or ≤−1.5, p < .05), identified 1207 DEGs in 1DH (706 upregulated, 501 downregulated), 783 DEGs in 2DH (409 upregulated, 374 downregulated) and 855 DEGs in 3DH (459 upregulated, 396 downregulated) relative to normoxia (Figure 1E–1F). Across all time points, 146 genes were consistently upregulated, and 116 were consistently downregulated (Figure 1G).

Functional enrichment analysis (KEGG and biological process terms) revealed that hypoxia-regulated genes were enriched in pathways related to hypoxia homeostasis, epithelial-to-mesenchymal transition, estrogen resistance, TNFα signalling, mitotic spindle formation and inflammation (Figure 1H–1I). Of note, a subset of 13 genes (ASPM, AURKA, CCNA2, CCNB1, CDCA3, CENPF, DLGAP5, KIF11, KIF20A, KIFC1, MMP3, MTIX and TPX2) showed transient upregulation at 1DH but downregulation at 2DH and 3DH (Figure 1G, right panel). These genes are primarily involved in microtubule cytoskeleton organisation and mitotic regulation, highlighting the disruptive effect of hypoxia on cell division and cell cycle progression.

Network Analysis Identifies Hypoxia-related Modules

To explore the functional relationships among hypoxia-regulated genes, a PPI network was constructed. A total of 275 overlapping DEGs were uploaded into the online STRING database to gain PPI information and were visualised in Cytoscape, which resulted in 241 nodes and 334 edges with a PPI enrichment p value of 3.33e-16 (Figure 2A).

Figure 2. Protein–protein Interaction (PPI) Network and Analysis of Functionally Related Modules.

Figure 2.

Notes: (A) PPI network of the differentially expressed genes constructed using Cytoscape. Red dots represent upregulated genes and green dots represent down-regulated genes. The cluster of white dots represents the genes upregulated in 1DH but downregulated in 2DH and 3DH. (B) The top two modules (gene clusters) were identified using the Molecular Complex Detection (MCODE) plugin from Cytoscape. MCODE identified two modules/clusters derived from the network of interactions between protein and protein—Module 1 (above) and Module 2 (below). Nodes represent genes, and edges indicate PPI. Functional enrichment analysis of genes in Module 1 and Module 2. The dot plot shows significantly enriched Gene Ontology biological processes (GO-BP) and KEGG pathways. The x-axis represents gene ratio, and the dot size indicates gene count. Colour gradient reflects adjusted p values.

Module detection using Cytoscape with the MCODE plugin using the cutoff MCODE score >5 and number of nodes ≥5, identified six significant clusters (Supplementary Table 1). Cluster 1 (annotated as module 1; score = 13; nodes = 13; edges = 78) showed the highest density, size and cohesive core module. Module 1 consisted of 13 genes (CDCA2, CCNA2, KIF11, CENPF, KIFC1, CDCA3, RACGAP1, KIF20A, TPX2, ASPM, AURKA, DLGAP5 and CCNB1) that are predominantly involved in cell cycle regulation and mitosis (Figure 2B). Again, Cluster 3 (annotated as module 2; score = 6; nodes = 9; edges = 24) also showed strongly topologically significant genes and contained functionally coherent genes enriched in chemokine signalling pathways (Figure 2B). Another significant module consisting of histone-related proteins (Supplementary Figure 1) also emerged from the analysis. Interestingly, many Module 1 genes overlapped with the subset of DEGs that were transiently upregulated at 24 h of hypoxia and subsequently downregulated under prolonged exposure, suggesting dynamic regulation of mitotic pathways in response to hypoxic stress.

Functional enrichment analysis of the MCODE modules using the DAVID database further confirmed associations with key cell division processes, including spindle organisation, chromosome segregation and mitotic spindle assembly (Figure 2B). These results highlight that hypoxia primarily influences genes associated with cell cycle control and mitosis.

Prioritisation of Hub Genes by CytoHubba

To identify the most influential genes within the PPI network, hub gene analysis was performed using the CytoHubba plugin. Genes were ranked based on five topological measures: closeness, degree, EPC, MCC and MNC. The top 30 genes from 275 DEGs in the PPI network were evaluated using five calculation methods (MCC, MNC, degree, EPC and closeness) employing CytoHubba in Cytoscape, and their scores in each of the methods used are represented in Supplementary Table 2. The intersection of the top 20-ranked genes across these parameters was considered the set of candidate hub genes (Figure 3A).

Figure 3. Biological Significance of the Hub Genes in Glioma.

Figure 3.

Notes: (A) Twenty genes were identified by CytoHubba through the intersection of five topological analyses. (B) A Venn diagram showing that 18 of the 20 selected genes were found in Module 1, identified by MCODE. (C) PPI network of the 18 hub genes identified by CytoHubba and MCODE. (D) Biological process enrichment analysis of the hub genes using ClueGO and CluePedia. (E) Expression of the hub genes (ASPM, AURKA, CCL2, CCNA2, CCNB1, CDCA2, CDCA3, CENPF, CTGF, CXCL8, DLGAP5, EGR1, KIF20A, KIFC1, PTGS2, RACGAP1 and TPX1) in normal versus glioma samples.

Further refinement was performed by overlapping CytoHubba-ranked genes with those from the MCODE modules, resulting in a set of 18 hypoxia-related hub genes: KIF20A, KIFC1, CCNB1, CXCL8, AURKA, EGR1, CDCA3, CENPF, CDCA2, ASPM, KIF11, CCL2, CCNA2, DLGAP5, RACGAP1, TPX2, PTGS2 and CTGF (Figure 3B). PPI analysis using the STRING database revealed that the CytoHubba-derived hub genes are highly interconnected (p value < 1.0e-16; Figure 3C), indicating their possible involvement in shared biological pathways. Furthermore, functional enrichment of these hub genes using ClueGO and CluePedia revealed strong associations with mitotic processes, including spindle organisation, centrosome localisation, spindle assembly and chromosome segregation (Figure 3D). Sixteen out of the top 17 enriched terms corresponded to mitosis and cell division, underscoring the central role of these hub genes in glioma biology.

Validation in clinical data sets using the ONCOMINE database confirmed that all hub genes except KIF11 were significantly upregulated in at least two independent glioma patient cohorts (Figure 3E). These results demonstrate that hypoxia-regulated hub genes are strongly linked to mitotic control and are consistently dysregulated in glioma, suggesting their potential as therapeutic targets.

Prognostic Relevance and Validation of Hypoxia-regulated Hub Genes

To assess the prognostic value of the identified hub genes, survival analysis was performed using the Gliovis platform. Sixteen of the 18 hub genes (KIF20A, CCNB1, AURKA, EGR1, CDCA3, CENPF, CDCA2, ASPM, KIF11, CCL2, CCNA2, DLGAP5, RACGAP1, TPX2, PTGS2 and CTGF) were significantly associated with OS in glioma patients (p < .05) (Figure 4A). Elevated expression of these genes correlated with shorter OS, highlighting their potential as clinically relevant prognostic markers in glioma (Supplementary Table 3).

Figure 4. Prognostic Significance of the Hub Genes in Glioma.

Figure 4.

Notes: (A) The prognostic significance of the hub genes in patients with glioma, according to the Gliovis database. The red lines represent patients with high gene expression, and the blue lines represent patients with low gene expression. The HR, median survival, and p values are represented as legends of each graph (upper right). (B) Validation of expression of some of the hub genes: KIF20A, CCNB1, AURKA, CCNA2, KIFC1 and CENPF in normoxia and hypoxia (0.1% 1DH, 2DH and 3DH) by qRT-PCR in U87MG glioma cells. Data are represented as fold change ± SEM calculated using technical triplicate data in three independent biological replicates. *p < .05, **p < .01, ***p < .001.

Given their prognostic importance, we next evaluated the expression dynamics of selected hub genes under hypoxic stress. qRT-PCR analysis of six candidates (KIF20A, KIFC1, CENPF, AURKA, CCNA2 and CCNB1) was conducted in U87MG cells cultured under normoxia and hypoxia (1DH, 2DH, 3DH). In line with the microarray results, transcript levels were significantly upregulated at 1DH but declined with prolonged hypoxia (2DH and 3DH) (Figure 4B). Notably, at 3DH, KIF20A, AURKA and KIFC1 expression remained higher than in normoxia (fold change > 1), whereas CCNA2 and CENPF returned to near-baseline levels.

Analysis of the key mediators of hypoxia response, HIF-1α and HIF-2α, in LN229 GBM cells cultured in hypoxia exhibited significant downregulation in many of the hub genes analysed (Supplementary Figure 2), signifying that downregulation of HIFs reduces the hypoxia-induced changes in GBM cells, although not significantly. These findings indicate a dynamic, time-dependent regulatory adjustment of cell cycle-associated genes in response to progressive hypoxic stress within the tumour microenvironment of gliomas. The analysis confirms that hypoxia-induced response occurs across genetically heterogeneous GBM cells.

Discussion

Hypoxia represents a defining microenvironmental hallmark of GBM, shaping its genetic, metabolic and immunological landscape.15–17 Prolonged hypoxia acts as a potent inducer of genomic instability and phenotypic plasticity in GBM, leading to compromised DNA repair.18, 19 The present study identifies 18 hypoxia-associated hub genes clustered around cell cycle, mitotic control and immune regulation—molecular systems central to tumour adaptability under low oxygen tension. These findings underscore the interplay between oxygen deprivation and transcriptional reprogramming, which collectively sustain glioma proliferation, invasion and resistance to therapy.

The upregulation of kinesins (KIF20A, KIF11, KIFC1), cyclins (CCNA2, CCNB1) and cell division-associated proteins (CDCA2, CDCA3) aligns with the proliferative and invasive behaviour of hypoxic tumour cells.20–23 These gene families orchestrate spindle assembly, mitotic checkpoint regulation and chromatin remodelling, reflecting an adaptive proliferative response that sustains tumour growth despite metabolic stress.24–30 The identification of these molecular signatures complements previous reports linking chronic hypoxia to dysregulated DNA repair and repeat element incorporation, mechanisms that promote oncogenic evolution within the glioma microenvironment. 18

Among the identified hub genes, AURKA, CENPF and CTGF demonstrate consistent upregulation across independent data sets and significant association with poor clinical outcomes. AURKA, beyond its canonical mitotic role, operates as a metabolic hub through regulation of c-Myc and glycolytic pathways, conferring treatment resistance under hypoxia.31, 32 CENPF, a kinetochore protein responsive to hypoxic stress, integrates p53 and MAPK signalling to modulate cell-cycle checkpoints,33, 34 while CTGF participates in extracellular matrix remodelling and angiogenic signalling.35, 36 The convergence of these molecules highlights a coordinated transcriptional network that links hypoxia to both proliferative and migratory phenotypes in GBM.

In addition to promoting cell division, hypoxia-induced transcriptional programmes remodel the immune microenvironment. Chemokines such as CCL2, among the identified hub genes, mediate recruitment of regulatory T cells and myeloid-derived suppressor cells, reinforcing GBM’s immunosuppressive niche.37, 38 These molecules also activate ERK1/2-driven signalling in tumour-associated macrophages, promoting pseudopodia formation and glioma invasiveness.38, 39 Such dual functionality, amplifying tumour aggressiveness while attenuating immune surveillance, illustrates the multifaceted impact of hypoxia-responsive genes on tumour–host interactions. Our results align with recent single-cell and spatial transcriptomic studies that highlight the heterogeneous hypoxic tumour-driven programmes in GBM. For example, single-cell RNA sequencing has identified a distinct hypoxic tumour cell subpopulation localised within the tumour core, characterised by enhanced invasiveness and macrophage interactions mediated by transcription factors such as CEBPD and FOSL1. 40 Similarly, combined single-cell RNA and ATAC (scMultiome) analyses revealed that chronic hypoxia remodels both transcriptional and chromatin landscapes to maintain glioma stem cell proliferation under low oxygen tension. 41 Spatial single-cell proteomic mapping further demonstrated that hypoxic niches in GBM harbour unique metabolic, stemness and immune signatures, including lymphocyte depletion and reprogramming of myeloid states. 42 These complementary findings highlight the dynamic, spatially distinct adaptations induced by hypoxia at both the cellular and microenvironmental levels and provide a broader context for the regulatory adjustments of hub genes observed in our data set. Trends in publicly available microarray data sets showed that HIF inhibition can modulate the downstream effector function of many of these genes.

Interestingly, sustained hypoxia did not uniformly maintain transcriptional activation of hub genes. Instead, many exhibited transient upregulation during early hypoxia (1DH) followed by a decline and modest rebound under chronic conditions (2DH-3DH). This biphasic response may reflect a diapause-like adaptive state, a reversible phase of metabolic quiescence that allows tumour cells to survive prolonged oxygen deprivation. 43 Comparable transcriptional dormancy programmes have been documented in colorectal cancer, mediated by proteins such as SMC4, which regulate lactate metabolism and chemotherapy resistance. 44 Moreover, treatment-persistent tumour cells across multiple cancers exhibit transcriptional states resembling diapause, involving suppression of MYC and mTOR pathways. Disruption of this adaptive programme, for example by targeting MYC activity, has been shown to enhance chemosensitivity. 45 These findings suggest that GBM cells utilise hypoxia-induced dormancy as a survival-adaptive strategy, a concept with implications for therapeutic design targeting resistant tumour cell subpopulations.

The identification of hypoxia-modulated hub genes integrates cell cycle regulation, immune modulation and stress adaptation into a unified model of GBM progression. These genes hold diagnostic and prognostic potential and represent promising candidates for therapeutic intervention targeting hypoxia-driven oncogenic pathways. The dynamic regulation of their expression also challenges static models of hypoxia response, emphasising the need for temporal and spatial analyses to elucidate molecular switching events governing glioma survival strategies.

Beyond GBM, hypoxia-induced molecular alterations have profound implications for the pathogenesis of other nervous system diseases. 46 Notably, hypoxic lesions in Alzheimer’s disease drive amyloidogenic processing via HIF-1α-mediated upregulation of β-secretase, contributing to plaque formation and neuronal death. 47 Hypoxia further exacerbates neuroinflammation and calcium dysregulation, which are pivotal in AD progression. 48 Similar hypoxia-driven mechanisms are implicated in stroke and traumatic brain injury, where HIF-1α regulates neurogenesis and metabolic adaptation. Thus, the hypoxia-responsive hub genes identified here reflect a broader molecular framework relevant to multiple neurodegenerative and neurovascular disorders, underscoring the translational potential of targeting hypoxia-adaptive pathways across nervous system diseases. Overall, these findings advance the understanding of how hypoxia orchestrates GBM’s molecular complexity, providing a mechanistic framework for future studies aimed at developing dual-targeting strategies combining cell cycle inhibition with modulation of hypoxia-adaptive pathways.

Acknowledgements

MKS acknowledges the Senior Research Fellowship from ICMR. JC is grateful for the Junior Research Fellowship from the Department of Biotechnology (DBT), Senior Research Fellowship (SRF) from the Indian Council of Medical Research (ICMR) and Research Associateship from DBT (DBT-RA). SS is a National Science Chair awardee of the ANRF, India; NSC/2022/000054. The Central Instrumentation Facility at UDSC has provided us with access to many equipment and facilities.

The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding: The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: The work was supported by ICMR (IIRP 2023-1868), SERB (SPG/2021/004574), SERB (CRG 2016/003523) and DBT (BT/PR14722/BRB/10/2010) granted to TS and National Science Chair (NSC/2022/000054) of the Science and Engineering Board (SERB), India, awarded to SS. Funding from the Department of Biotechnology, Indian Council of Medical Research (ICMR), Science and Engineering Research Board (SERB-CRG, SERB-POWER), University of Delhi—IoE-FRP and IoE-MRP to TS is gratefully acknowledged. The authors are thankful for the DST-FIST Level 2 funding to the Department of Genetics.

ORCID iD: Tapasya Srivastava Inline graphic https://orcid.org/0000-0002-3358-2225

Author’s Contribution

MKS: Study design, culture of cells, RT-PCR, western blotting, microarray; JC: Culture of cells for validation of hub genes, qRT-PCR, bioinformatic analysis, first draft of manuscript. AB: Bioinformatic pipeline and analysis, KC: Resources, editing of manuscript, SS: Study design, resources, funding and editing of manuscript; TS: Study design, experiments, resources, funding, editing of manuscript.

Data Availability

The data supporting this article have been included as part of the Supplementary Information.

Statement of Ethics and Patient Consent

This study did not involve any human participants, human data, or human tissue. Therefore, ethics approval and informed consent for participation are not applicable.

Supplementary Material

Supplementary material for this article is available online.

Supplemental Material for Integrative Transcriptomic Analysis Identifies Hypoxia-responsive Cell Cycle Hub Genes as Prognostic Markers in Glioblastoma by Manish K. Sharma, Jonita Chongtham, Ashish Bhushan, Kunzang Chosdol, Subrata Sinha and Tapasya Srivastava, in Annals of Neurosciences

References

  • 1.Numan T, Breedt LC, Maciel B de APC, et al. Regional healthy brain activity, glioma occurrence and symptomatology. Brain 2022; 15(1): 3654–3665. DOI: 10.1093/brain/awac180 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Mallick S, Gandhi AK, and Rath GK.. Therapeutic approach beyond conventional temozolomide for newly diagnosed glioblastoma: review of the present evidence and future direction. Indian J Med Paediatr Oncol 2015; 36(4): 229–237. DOI: 10.4103/0971-5851.171543 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Park JH and Lee HK.. Current understanding of hypoxia in glioblastoma multiforme and its response to immunotherapy. Cancers 2022; 14(5): 1176. DOI: 10.3390/cancers14051176 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Hubbi ME, Gilkes DM, Hu H, et al. Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression. Proc Natl Acad Sci U S A 2014; 111(32): E3325–E3334. DOI: 10.1073/pnas.1412840111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Giam M and Rancati G.. Aneuploidy and chromosomal instability in cancer: a jackpot to chaos. Cell Div 2015; 10(1): 3. DOI: 10.1186/s13008-015-0009-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Druker J, Wilson JW, Child F, et al. Role of hypoxia in the control of the cell cycle. Int J Mol Sci 2021; 22(9): 4874. DOI: 10.3390/ijms22094874 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Obacz J, Pastorekova S, Vojtesek B, et al. Cross-talk between HIF and p53 as mediators of molecular responses to physiological and genotoxic stresses. Mol Cancer 2013; 12(1): 1–10. DOI: 10.1186/1476-4598-12-93 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Shi S-N, Qin X, Wang S, et al. Identification of potential novel differentially-expressed genes and their role in invasion and migration in renal cell carcinoma. Aging 2020; 12(10): 9205–9223. DOI: 10.18632/aging.103192 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature Commun 2019; 10(1): 1523. DOI: 10.1038/s41467-019-09234-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucl Acids Res 2019; 47(Database issue): D607–D613. DOI: 10.1093/nar/gky1131 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Shannon P. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13(11): 2498–2504. DOI: 10.1101/gr.1239303 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Chin C-H, Chen S-H, Wu H-H, et al. CytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol 2014; 8(Suppl 4): S11. DOI: 10.1186/1752-0509-8-s4-s11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Bowman RL, Wang Q, Carro A, et al. GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro-Oncology 2017; 19(1): 139–141. DOI: 10.1093/neuonc/now247 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6(1): 1–6. DOI: 10.1016/s1476-5586(04)80047-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Bray F, Laversanne M, Sung H, et al. Global Cancer Statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3): 229–263. DOI: 10.3322/caac.21834 [DOI] [PubMed] [Google Scholar]
  • 16.Ceccarelli M, Barthel FP, Malta TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 2016; 164(3): 550–563. DOI: 10.1016/j.cell.2015.12.028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Luoto KR, Kumareswaran R, and Bristow RG.. Tumor hypoxia as a driving force in genetic instability. Genome Integr 2013; 4(1): 5. DOI: 10.1186/2041-9414-4-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Pal A, Srivastava T, Sharma MK, et al. Aberrant methylation and associated transcriptional mobilization of Alu elements contributes to genomic instability in hypoxia. J Cell Mol Med 2009; 14(11): 2646–2654. DOI: 10.1111/j.1582-4934.2009.00792.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Yuan J, Hu Z, Mahal BA, et al. Integrated analysis of genetic ancestry and genomic alterations across cancers. Cancer Cell 2018; 34(4): 549–560. DOI: 10.1016/j.ccell.2018.08.019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Baldwin RM, Barrett GM, Parolin DA, et al. Coordination of glioblastoma cell motility by PKCι. Mol Cancer 2010; 9(1): 233. DOI: 10.1186/1476-4598-9-233 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Zhou Y, Xu M-F, Chen J, et al. Loss-of-function of kinesin-5 KIF11 causes microcephaly, chorioretinopathy, and developmental disorders through chromosome instability and cell cycle arrest. Exp Cell Res 2024; 436(1): 113975. DOI: 10.1016/j.yexcr.2024.113975 [DOI] [PubMed] [Google Scholar]
  • 22.Duan J, Huang W, and Shi H.. Positive expression of KIF20A indicates poor prognosis of glioma patients. OncoTargets Ther 2016; 9: 6741–6749. DOI: 10.2147/ott.s115974 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Liu B, Zhang G, Cui S, et al. Upregulation of KIF11 in TP53 mutant glioma promotes tumor stemness and drug resistance. Cell Mol Neurobiol 2021; 42(5): 1477–1485. DOI: 10.1007/s10571-020-01038-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Valensin S, Ghiron C, Lamanna C, et al. KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain. BMC Cancer 2009; 9(1): 196. DOI: 10.1186/1471-2407-9-196 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Wu J, Wang X, Yuan X, et al. Kinesin family member C1 increases temozolomide resistance of glioblastoma through promoting DNA damage repair. Cell Transplant 2021; 30: 096368972199146. DOI: 10.1177/0963689721991466 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 26.Arsic N, Bendris N, Peter M, et al. A novel function for cyclin A2: control of cell invasion via RhoA signaling. J Cell Biol 2012; 196(1), 147–162. DOI: 10.1083/jcb.201102085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zhou H-Y, Wang Y-C, Wang T, et al. CCNA2 and NEK2 regulate glioblastoma progression by targeting the cell cycle. Oncol Lett 2024; 27(5): 206. DOI: 10.3892/ol.2024.14339 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Gavet O and Pines J.. Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell 2010; 18(4): 533–543. DOI: 10.1016/j.devcel.2010.02.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Vagnarelli P. Repo-man at the intersection of chromatin remodelling, DNA repair, nuclear envelope organization, and cancer progression. Adv Exp Med Biol 2014; 773: 401–414. DOI: 10.1007/978-1-4899-8032-8_18 [DOI] [PubMed] [Google Scholar]
  • 30.Adams MN, Burgess JT, He Y, et al. Expression of CDCA3 is a prognostic biomarker and potential therapeutic target in non-small cell lung cancer. J Thorac Oncol 2017; 12(7): 1071–1084. DOI: 10.1016/j.jtho.2017.04.018 [DOI] [PubMed] [Google Scholar]
  • 31.Nguyen TT, Silva FN, and Golemis EA.. Aurora kinases as therapeutic targets in head and neck cancer. Cancer J 2022; 28(5): 387–400. DOI: 10.1097/ppo.0000000000000614 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Du R, Huang C, Liu K, et al. Targeting AURKA in cancer: molecular mechanisms and opportunities for cancer therapy. Mol Cancer 2021; 20(1): 15. DOI: 10.1186/s12943-020-01305-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Zhang M, Zhang Q, Bai J, et al. Transcriptome analysis revealed CENPF associated with glioma prognosis. Math Biosci Eng 2021; 18(3): 2077–2096. DOI: 10.3934/mbe.2021107 [DOI] [PubMed] [Google Scholar]
  • 34.Wang D, Xu W, Huang M, et al. CENPF knockdown inhibits adriamycin chemoresistance in triple-negative breast cancer via the Rb-E2F1 axis. Sci Rep 2023; 13(1): 1803. DOI: 10.1038/s41598-023-28355-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Xie D, Yin D, Wang H-J, et al. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 2004; 10(6): 2072–2081. DOI: 10.1158/1078-0432.ccr-0659-03 [DOI] [PubMed] [Google Scholar]
  • 36.Yin D, Chen W, O’Kelly J, et al. Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. Int J Cancer 2010; 127(10): 2257–2267. DOI: 10.1002/ijc.25257 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Chang AL, Miska J, Wainwright DA, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Res 2016; 76(19): 5671–5682. DOI: 10.1158/0008-5472.CAN-16-0144 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Takacs GP, Kreiger CJ, Luo D, et al. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2+/CX3CR1+ M-MDSCs into the tumor microenvironment in a redundant manner. Front Immunol 2023; 13: 993444. DOI: 10.3389/fimmu.2022.993444 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Zhang X, Chen L, Dang W, et al. CCL8 secreted by tumor-associated macrophages promotes invasion and stemness of glioblastoma cells via ERK1/2 signaling. Lab Invest 2019; 100(4): 619–629. DOI: 10.1038/s41374-019-0345-3 [DOI] [PubMed] [Google Scholar]
  • 40.Zhang Y, Zhang B, Lv C, et al. Single-cell RNA sequencing identifies critical transcription factors of tumor cell invasion induced by hypoxia microenvironment in glioblastoma. Theranostics 2023; 13(11): 3744–3760. DOI: 10.7150/thno.81407 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Johnson AL and Lopez-Bertoni H.. Cellular diversity through space and time: adding new dimensions to GBM therapeutic development. Front Gene 2024; 15: 1356611. DOI: 10.3389/fgene.2024.1356611 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Nicholson JG, Cirigliano S, Singhania R, et al. Chronic hypoxia remodels the tumor microenvironment to support glioma stem cell growth. Acta Neuropathologica Commun 2024; 12(1): 46. DOI: 10.1186/s40478-024-01755-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Keshri R, Mathieu J, and Ruohola-Baker H.. Fight, flight, and freeze! Cell Metabol 2023; 35(9): 1493–1495. DOI: 10.1016/j.cmet.2023.08.007 [DOI] [PubMed] [Google Scholar]
  • 44.Sun X, He L, Liu H, et al. The diapause-like colorectal cancer cells induced by SMC4 attenuation are characterized by low proliferation and chemotherapy insensitivity. Cell Metabol 2023; 35(9): 1563–1579. DOI: 10.1016/j.cmet.2023.07.005 [DOI] [PubMed] [Google Scholar]
  • 45.Dhimolea E, de Matos Simoes R, Kansara D, et al. An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence. Cancer Cell 2021; 39(2): 240–256. DOI: 10.1016/j.ccell.2020.12.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Chen H, Ma D, Yue F, et al. The potential role of hypoxia-inducible factor-1 in the progression and therapy of central nervous system diseases. Curr Neuropharmacol 2022; 20(9): 1651–1666. DOI: 10.2174/1570159x19666210729123137 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Ogunshola OO and Antoniou X.. Contribution of hypoxia to Alzheimer’s disease: is HIF-1α a mediator of neurodegeneration? Cell Mol Life Sci 2009; 66(22): 3555–3563. DOI: 10.1007/s00018-009-0141-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Merelli A, Repetto M, Lazarowski A, et al. Hypoxia, oxidative stress, and inflammation: three faces of neurodegenerative diseases. J Alzheimer’s Dis 2021; 82: S109–S126. DOI: 10.3233/jad-201074 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary material for this article is available online.

Supplemental Material for Integrative Transcriptomic Analysis Identifies Hypoxia-responsive Cell Cycle Hub Genes as Prognostic Markers in Glioblastoma by Manish K. Sharma, Jonita Chongtham, Ashish Bhushan, Kunzang Chosdol, Subrata Sinha and Tapasya Srivastava, in Annals of Neurosciences

Data Availability Statement

The data supporting this article have been included as part of the Supplementary Information.


Articles from Annals of Neurosciences are provided here courtesy of SAGE Publications

RESOURCES